MedTrace Logo

Immunoprevention for High-risk Lung Lesions

NCT07284485 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2026-03-10

No results posted yet for this study

Summary

The main purpose of this study is to assess nadunolimab as an immunoprevention strategy for high-risk lung nodules in participants who are current or former tobacco smokers. The study may last up to 5 years for each participant.

Conditions

  • High-risk Lung Nodules

Interventions

BIOLOGICAL

Nadunolimab

Nadunolimab will be administered 10mg/kg intravenously every 3 weeks for 4 doses

Sponsors & Collaborators

  • Cantargia AB

    collaborator INDUSTRY

  • Robert Samstein

    lead OTHER

Principal Investigators

  • Robert M Samstein, MD, PhD · Icahn School of Medicine at Mount Sinai

  • Thomas Marron, MD, PhD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2027-12-15
Completion
2029-12-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07284485 on ClinicalTrials.gov